Genocea Biosciences, Inc.
We are a biopharmaceutical company that discovers and develops novel cancer immunotherapies using the ATLAS™ proprietary discovery platform. The ATLAS platform profiles each patient's CD4+ and CD8+ T cell immune responses to every potential target or “antigen” in that patient's tumor.
Last Closing Price
June 20, 2019
LEERINK SWANN & COMPANY
This offering is no longer available
Sign Up to participate in future offerings
To view the prospectus for Genocea Biosciences, Inc., or any offering listed on ClickIPO,
download the ClickIPO app...
or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277